Copertina

Mapping the Clinical Development Trajectory of Cell and Gene Therapy Products

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Magdi Elsallab, Michelle Ouvina, Andrea Arfe, Florence T. Bourgeois
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Clinical Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
di: Prathap Nagaraja Shastri, et al.
Pubblicazione: (2024)

Clinical Pharmacology Considerations for the “Off‐the‐Shelf” Allogeneic Cell Therapies
di: Hardik Mody, et al.
Pubblicazione: (2024)

Correction to “Clinical Pharmacology and Translational Considerations in the Development of CRISPR‐Based Therapies”
Pubblicazione: (2025)

Divergent Paths, Convergent Goals: Institutional Experiments in Cell and Gene Therapy Regulation and Payment Between China and the United States
di: Jiajv Chen, et al.
Pubblicazione: (2026)

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy
di: Michael T. Eadon, et al.
Pubblicazione: (2025)

Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology
di: Mohamed Elmeliegy, et al.
Pubblicazione: (2024)

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy
di: Katherine M. Robinson, et al.
Pubblicazione: (2024)

Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
di: Wenqi Dong, et al.
Pubblicazione: (2025)

Tailoring Drug Therapy: Bridging Data Science and Clinical Reality
di: Karen Rowland Yeo
Pubblicazione: (2026)

PharmVar GeneFocus: CYP4F2
di: Pablo Zubiaur, et al.
Pubblicazione: (2024)

PharmVar GeneFocus : NAT2 — Genetic Variation and Updated Nomenclature
di: Georgia Papanikolaou, et al.
Pubblicazione: (2025)

From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy
di: Lisa Cuba, et al.
Pubblicazione: (2024)

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
di: Vaishali Sahasrabudhe, et al.
Pubblicazione: (2025)

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov
di: Chunhui Huang, et al.
Pubblicazione: (2024)

Analysis by Age, Sex, Race, and Ethnicity of Participants in Clinical Trials Supporting Recently Approved Novel Therapies
di: Neali H. Lucas, et al.
Pubblicazione: (2025)

The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making
di: Mary Summer Starling, et al.
Pubblicazione: (2024)

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions
di: Leila Potzel, et al.
Pubblicazione: (2026)

From Challenge to Opportunity: How Shwachman–Diamond Syndrome Became a Promising Target for Therapy Development
di: Eszter S. Hars, et al.
Pubblicazione: (2024)

Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
di: Mohamed A. Kamal, et al.
Pubblicazione: (2024)

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
di: Simeon Rüdesheim, et al.
Pubblicazione: (2025)

Dietary‐Driven Gene Expansion
di: Magnus Ingelman‐Sundberg
Pubblicazione: (2025)

Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals
di: Ting Wang, et al.
Pubblicazione: (2025)

Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease
di: Chanchala Kaddi, et al.
Pubblicazione: (2024)

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development
di: Robin DiFrancesco, et al.
Pubblicazione: (2026)

Innovations in Clinical Pharmacology: Shaping the Future of Evidence Generation in Research, Development, and Utilization of Medicines
di: Karthik Venkatakrishnan, et al.
Pubblicazione: (2025)

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
di: Amitava Mitra, et al.
Pubblicazione: (2024)

Model‐Based Prediction of Clinically Relevant Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation
di: Katharina M. Götz, et al.
Pubblicazione: (2025)

A Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference Products
di: Cristina Fernandez‐Mendivil, et al.
Pubblicazione: (2024)

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
di: John D. Davis, et al.
Pubblicazione: (2024)

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
di: KyoungSoo Lim, et al.
Pubblicazione: (2024)

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development
di: Tanja S. Zabka, et al.
Pubblicazione: (2025)

Regulatory Approval of CAR‐T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan
di: Kensuke Matsuda, et al.
Pubblicazione: (2025)

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy
di: Julio D. Duarte, et al.
Pubblicazione: (2024)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
di: Jatinder Kaur Mukker, et al.
Pubblicazione: (2025)

Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases
di: Chiara Zecchin, et al.
Pubblicazione: (2026)

Model‐Informed Precision Dosing Using Machine Learning for Levothyroxine in General Practice: Development, Validation and Clinical Simulation Trial
di: Jules M. Janssen Daalen, et al.
Pubblicazione: (2024)

Reply to: “Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis”
di: Polly Paul, et al.
Pubblicazione: (2025)

Use of PopPK and E‐R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma‐Based Therapies and Clinical Effects in cTTP
di: Munjal Patel, et al.
Pubblicazione: (2025)

Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and Vaccine Development: Bridging Translational and Platform Gaps for Enhanced Decision Making
di: Linh M. Van, et al.
Pubblicazione: (2025)

An Update to the Clinical Pharmacogenetics Implementation Consortium ( CPIC ) SLCO1B1 Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub‐Saharan African Ancestry
di: Akinyemi Oni‐Orisan, et al.
Pubblicazione: (2025)